A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

William A. Sheremata; T. L. Vollmer; L. A. Stone; A. J. Willmer-Hulme; M. Koller

doi:10.1212/wnl.52.5.1072

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

William A. Sheremata, T. L. Vollmer, L. A. Stone, A. J. Willmer-Hulme, M. Koller

Neurology

Research output: Contribution to journal › Article › peer-review

114 Scopus citations

Abstract

A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.

Original language	English (US)
Pages (from-to)	1072-1074
Number of pages	3
Journal	Neurology
Volume	52
Issue number	5
DOIs	https://doi.org/10.1212/wnl.52.5.1072
State	Published - Mar 23 1999

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/wnl.52.5.1072

Fingerprint Dive into the research topics of 'A safety and pharmacokinetic study of intravenous natalizumab in patients with MS'. Together they form a unique fingerprint.

Cite this

@article{66993ee9c2c549fda470f937849b6daf,

title = "A safety and pharmacokinetic study of intravenous natalizumab in patients with MS",

abstract = "A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.",

author = "Sheremata, {William A.} and Vollmer, {T. L.} and Stone, {L. A.} and Willmer-Hulme, {A. J.} and M. Koller",

year = "1999",

month = mar,

day = "23",

doi = "10.1212/wnl.52.5.1072",

language = "English (US)",

volume = "52",

pages = "1072--1074",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

AU - Sheremata, William A.

AU - Vollmer, T. L.

AU - Stone, L. A.

AU - Willmer-Hulme, A. J.

AU - Koller, M.

PY - 1999/3/23

Y1 - 1999/3/23

N2 - A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.

AB - A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.

UR - http://www.scopus.com/inward/record.url?scp=0033596831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033596831&partnerID=8YFLogxK

U2 - 10.1212/wnl.52.5.1072

DO - 10.1212/wnl.52.5.1072

M3 - Article

C2 - 10102433

AN - SCOPUS:0033596831

VL - 52

SP - 1072

EP - 1074

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -